Bactiguard receives product approval in Egypt

The product approval for Bactiguard’s urinary (Foley) catheters has been announced by the Egyptian Ministry of Health. This opens new opportunities for Bactiguard in providing effective infection prevention in the most populous country in North Africa and the Middle East.

“We are finally through the registration process in Egypt, which started more than an year ago and was longer than expected. This is a breakthrough and together with our distributor Heal Pharma, we can now start the launch activities in the most populous country in the region”, says Jonas Östregård, SVP Sales and continues:

“Most countries are facing challenges in the healthcare sector including hospital acquired infections and there is an growing need for preventive solutions. With Bactiguard’s portfolio for infection protection, starting with the BIP Foley Catheter, we are convinced that Egypt will be able to reduce infections and limit the use of antibiotics and become one of our biggest markets in the region in a few years.”

Egypt is the most populous country in North Africa and the Middle East, with a population of more than 90 million people. Heal Pharma, based in Cairo, has a nationwide reach and was established in 2008 by Dr Mohamed Khalifa.

For further information, please contact:
Cecilia Edström, CFO mobile: +46 72 226 23 28

About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

 The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner CR Bard, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.

Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about how Bactiguard saves lives on www.bactiguard.com

Tags: